Managing Access to Medical Innovation: Strengthening the Methodology-Policy Nexus

Why Attend?

The ISPOR European Congress features three though-provoking plenary sessions and more than 2,600 presentations in the form of workshops, issue panels, forums, symposia, podium presentations, and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real world data, clinical, economic, and patient-reported outcomes.

- **Learn** new and novel applications in the conduct and use of HEOR.
- **Engage** with renowned experts in the field.
- **Network** with colleagues, collaborators, and clients.
- **Share** research, ideas, and developments in an open, objective environment.
- **Advance** your career by participating in the ISPOR Short Course Program.
- **Stay current** on HEOR regulatory and policy issues.

Learn. Apply. Advance.

ISPOR offers a series of Pre-Congress short (training) courses on trending topics in the health economics and outcomes research (HEOR) field, ranging from tried and true modeling, database, economic, preference-based, and outcomes research methodology courses. Many have particular relevance to Europe, such as *Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements* and *Reimbursement Systems for Pharmaceuticals / Biologics in Europe*. These courses range from introductory to advanced and many include hands-on training opportunities.

ISPOR 19th Annual European Congress

Program Highlights

First Plenary Session

What Synergies Could Be Created between Regulatory and Health Technology Assessments?

Decisions taken by regulators and health care payers, the latter informed by HTA bodies, determine which patient groups have access to new therapies and at what point in time. While these decision makers have different roles, they often rely on almost the same scientific data about new products; they also share the broad goal of enabling access for patients to beneficial therapies. Yet, formal interactions and collaboration between regulators and the HTA bodies that inform payers have only started in recent years in the European Union (EU) and are mostly in a pilot stage. This plenary session explores hitherto unrealised synergies in the work and processes of regulators and HTA bodies. Panelists will also address the roadblocks in the EU health sector ecosystem that need to be removed in order to realise the synergies while respecting their different roles.

Second Plenary Session

Differential Pricing of Medicines in Europe: Implications for Access, Innovation, and Affordability

Each year only 30 to 40 new patent-protected medicines are launched worldwide. From an economic perspective, they are unique global public goods—with high average fixed costs of development and low marginal costs of production and distribution. Given differences among countries in their ability and willingness to pay for healthcare, health economists have long argued that differential pricing for medicines across countries could improve global dynamic efficiency. But law in the European Union supporting the free movement of goods makes it difficult to maintain different prices in different countries. Countries have resorted to referencing prices in other countries to support their local pricing policies and negotiations, and have developed schemes that allow them to obtain confidential discounts. The resulting patterns of price differences and access limitations are falling far short of what a coherent approach might produce. This session will explore options for a defined and systematic approach to promoting efficient differential pricing in Europe. Operational and political feasibility are key considerations in moving toward a sustainable policy.

Third Plenary Session

How to Control Costs and Improve Access to Medicines: Lessons from the InterQuality Project

This session will describe a number of important themes emerging from the InterQuality Project. One key finding was the importance of equity of access to health services and medicines. For example, the proportion of households with "catastrophic" out-of-pocket health spending in Poland was much higher than in either Denmark or Germany, and concentrated in the worst-off groups of senior citizens. The new Minister of Health launched a program of free medicines for senior citizens of Poland. A second important theme was how evidence on patients' preferences can be integrated into health technology assessment (HTA) using efficiency frontier concept to identify the most efficient strategy within a disease class in regulatory decision making in Germany. Finally, while most European Union (EU) member states promote the implementation of innovative analytical methods or e-health tools, such as e-prescribing, these efforts are not part of an integrated package. Currently, no single agent manages insured patients' access to medicines and health care in a coordinated manner. More attention should be paid by EU member states to an institutional framework integrating the various methods and e-health tools to enhance benefits to both individuals and societies.

Program also includes: 31 Pre-Congress HEOR Short Courses • 2,500 Research Poster Presentations • 48 Research Podium Presentations • 20 Issue Panels • 33 Workshops • 12 ISPOR Forums

Registration Fees *(Exchange rate as of March 2016)*

CONGRESS REGISTRATION FEES	*THRU 20 SEPTEMBER 2016*	*AFTER 20 SEPTEMBER 2016*
Standard	Member €795 (US$875) Non-Member €932 (US$1025)	Member €895 (US$985) Non-Member €1032 (US$1135)
Clinical Practitioners (Clinical Practice, Hospital)	Member €595 (US$655) Non-Member €732 (US$805)	Member €695 (US$765) Non-Member €832 (US$915)
Full-Time Government and Academia	Member €495 (US$545) Non-Member €632 (US$695)	Member €595 (US$655) Non-Member €732 (US$805)
Patient Representative	Member €195 (US$215) Non-Member €332 (US$365)	Member €245 (US$270) Non-Member €382 (US$420)
Full-Time Students (must provide current enrollment docs)	Member €150 (US$165) Non-Member €182 (US$200)	Member €200 (US$220) Non-Member €232 (US$255)
One-Day Registration (per day) ❍ Oct 31 ❍ Nov 1 ❍ Nov 2	Member €425 (US$468) Non-Member €562 (US$618)	

CONGRESS ENHANCEMENT FEES	
ISPOR Social Event: Tuesday, 1 November, 8:00PM-11:30PM	€95 (US$105)

ISPOR 19th Annual European Congress

Short Courses Topics and Registration Fees

Economic Methods
– Introduction to Health Economic / Pharmacoeconomic Evaluations
– Statistical Methods for Pharmacoeconomics & Outcomes Research
– Cost-Effectiveness Analysis Alongside Clinical Trials
– Transferability of Cost-Effectiveness Data Between Countries
– Budget Impact Analysis I: A 6-Step Approach
– Budget Impact Analysis II: Applications & Design Issues

Modeling Methods
– Introduction to Modeling
– Development of Conceptual Models
– Pharmacoeconomic Modeling – Applications
– Bayesian Analysis – Overview and Applications
– Discrete Event Simulation for Economic Analyses – Concepts
– Understanding Survival Modeling with Application to HTA

Observational Data Methods
– Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources
– Use of Propensity Scores in Observational Studies of Treatment Effects
– Patient Registries
– Use of Instrumental Variables in Observational Studies of Treatment Effects
– Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness Studies
– Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices, and Acceptance in HTA

Outcomes Research Methods
– Meta-Analysis & Systematic Literature Review
– Network Meta-Analysis in Relative Effectiveness Research

Patient Preference Methods
– Collecting Health-State Utility Estimates for Economic Models in Clinical Studies
– Conjoint Analysis – Theory & Methods
– Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluation
– Mixed Methods Approaches for Patient-Centered Outcomes Research: Group Concept Mapping

Use of Pharmacoeconomic / Economic / Outcomes Research Information
– Elements of Pharmaceutical / Biotech Pricing
– Introduction to Health Technology Assessment
– Risk-Sharing / Performance-Based Arrangements for Drugs and Other Medical Products
– Introduction to the Economic Analysis of Diagnostics
– Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements
– Reimbursement Systems for Pharmaceuticals / Biologics in Europe
– Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

SHORT COURSE FEES		*THRU 20 SEPTEMBER 2016*	*AFTER 20 SEPTEMBER 2016*
ALL DAY COURSES:	Standard	€790 (US$869)	€890 (US$979)
	Clinical/Government/Academia	€590 (US$649)	€690 (US$759)
	Full-Time Students/Patient Representatives	€180 (US$198)	€230 (US$253)
HALF DAY COURSES:	Standard	€395 (US$435)	€445 (US$490)
	Clinical/Government/Academia	€295 (US$325)	€345 (US$380)
	Full-Time Students/Patient Representatives	€90 (US$99)	€115 (US$127)

CONGRESS ENHANCEMENT FEES	
Short Course Continuing Education Accreditation (CPE & CME)	€91 (US$100)

(Exchange rate as of March 2016)

Congress Promotional Opportunities

EXHIBIT *Register now! 5,220 attendees in 2015!*
Present your products and services to key outcomes researchers and health care decision makers in pharmaceutical, medical device & diagnostics, and biotechnology industries, as well as in clinical practice, government agencies, academia, and health care organizations. *www.ispor.org » ISPOR 19th Annual European Congress » Exhibit & Sponsorship*

SPONSOR *Increase your visibility! Give your company increased prominence!*
www.ispor.org » ISPOR 19th Annual European Congress » Exhibit & Sponsorship

ADVERTISE *Advertise in the Program & Schedule of Events!*
Advertising Deadline: 19 August 2016 *www.ispor.org » Advertising*